Visual acuity in patients with Leber's congenital amaurosis and early childhood-onset retinitis pigmentosa. 2010

Saloni Walia, and Gerald A Fishman, and Samuel G Jacobson, and Tomas S Aleman, and Robert K Koenekoop, and Elias I Traboulsi, and Richard G Weleber, and Mark E Pennesi, and Elise Heon, and Arlene Drack, and Byron L Lam, and Rando Allikmets, and Edwin M Stone
Department of Ophthalmology, University of Illinois at Chicago, Chicago, Illinois, USA.

OBJECTIVE To correlate visual acuity of patients with Leber's congenital amaurosis (LCA) and early childhood-onset retinitis pigmentosa (RP) with mutations in underlying LCA genes. METHODS Multicentered retrospective observational study. METHODS After exclusion of 28 subjects, 169 patients with the diagnosis of LCA and 27 patients with early childhood-onset RP were included in the study because the underlying mutations in AIPL1, GUCY2D, RDH12, RPE65, CRX, CRB1, RPGRIP1, CEP290, LCA5, and TULP1 genes could be identified in this cohort of patients. METHODS We collected data on best-corrected visual acuity as recorded at the time of the patient's most recent visit to one of the participating ophthalmology departments. The median and range of visual acuities for each genetic subtype were calculated separately for the LCA and early childhood-onset RP groups. METHODS The range and median best-corrected visual acuities for each genetic subtype and age-related mean visual acuities for each genetic subtype. RESULTS A wide variation in visual acuity was observed in patients with LCA and RPE65, RDH12, and CRB1 mutations, whereas AIPL1, GUCY2D, CRX, and RPGRIP1 gene mutations were associated with severely decreased visual acuities beginning within the first year of life. It was also noted that patients with either an RPE65 or CRB1 mutation have progressive visual loss with advancing age. Onset of visual symptoms after infancy was associated with a relatively better visual prognosis. CONCLUSIONS The data obtained from this study will help clinicians provide counseling on visual prognosis to patients with known mutations in LCA genes and be of value in future studies aimed at the treatment of LCA and early childhood-onset RP.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D008565 Membrane Proteins Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors. Cell Membrane Protein,Cell Membrane Proteins,Cell Surface Protein,Cell Surface Proteins,Integral Membrane Proteins,Membrane-Associated Protein,Surface Protein,Surface Proteins,Integral Membrane Protein,Membrane Protein,Membrane-Associated Proteins,Membrane Associated Protein,Membrane Associated Proteins,Membrane Protein, Cell,Membrane Protein, Integral,Membrane Proteins, Integral,Protein, Cell Membrane,Protein, Cell Surface,Protein, Integral Membrane,Protein, Membrane,Protein, Membrane-Associated,Protein, Surface,Proteins, Cell Membrane,Proteins, Cell Surface,Proteins, Integral Membrane,Proteins, Membrane,Proteins, Membrane-Associated,Proteins, Surface,Surface Protein, Cell
D008869 Microtubule-Associated Proteins High molecular weight proteins found in the MICROTUBULES of the cytoskeletal system. Under certain conditions they are required for TUBULIN assembly into the microtubules and stabilize the assembled microtubules. Ensconsin,Epithelial MAP, 115 kDa,Epithelial Microtubule-Associate Protein, 115 kDa,MAP4,Microtubule Associated Protein,Microtubule Associated Protein 4,Microtubule Associated Protein 7,Microtubule-Associated Protein,Microtubule-Associated Protein 7,E-MAP-115,MAP1 Microtubule-Associated Protein,MAP2 Microtubule-Associated Protein,MAP3 Microtubule-Associated Protein,Microtubule Associated Proteins,Microtubule-Associated Protein 1,Microtubule-Associated Protein 2,Microtubule-Associated Protein 3,7, Microtubule-Associated Protein,Associated Protein, Microtubule,E MAP 115,Epithelial Microtubule Associate Protein, 115 kDa,MAP1 Microtubule Associated Protein,MAP2 Microtubule Associated Protein,MAP3 Microtubule Associated Protein,Microtubule Associated Protein 1,Microtubule Associated Protein 2,Microtubule Associated Protein 3,Microtubule-Associated Protein, MAP1,Microtubule-Associated Protein, MAP2,Microtubule-Associated Protein, MAP3,Protein 7, Microtubule-Associated,Protein, Microtubule Associated,Protein, Microtubule-Associated
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D009419 Nerve Tissue Proteins Proteins, Nerve Tissue,Tissue Proteins, Nerve
D011506 Proteins Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein. Gene Products, Protein,Gene Proteins,Protein,Protein Gene Products,Proteins, Gene
D011956 Receptors, Cell Surface Cell surface proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behavior of the target cell (From Alberts, Molecular Biology of the Cell, 2nd ed, pp693-5). Cell surface receptors, unlike enzymes, do not chemically alter their ligands. Cell Surface Receptor,Cell Surface Receptors,Hormone Receptors, Cell Surface,Receptors, Endogenous Substances,Cell Surface Hormone Receptors,Endogenous Substances Receptors,Receptor, Cell Surface,Surface Receptor, Cell

Related Publications

Saloni Walia, and Gerald A Fishman, and Samuel G Jacobson, and Tomas S Aleman, and Robert K Koenekoop, and Elias I Traboulsi, and Richard G Weleber, and Mark E Pennesi, and Elise Heon, and Arlene Drack, and Byron L Lam, and Rando Allikmets, and Edwin M Stone
October 1996, Ophthalmology,
Saloni Walia, and Gerald A Fishman, and Samuel G Jacobson, and Tomas S Aleman, and Robert K Koenekoop, and Elias I Traboulsi, and Richard G Weleber, and Mark E Pennesi, and Elise Heon, and Arlene Drack, and Byron L Lam, and Rando Allikmets, and Edwin M Stone
January 2011, Clinical ophthalmology (Auckland, N.Z.),
Saloni Walia, and Gerald A Fishman, and Samuel G Jacobson, and Tomas S Aleman, and Robert K Koenekoop, and Elias I Traboulsi, and Richard G Weleber, and Mark E Pennesi, and Elise Heon, and Arlene Drack, and Byron L Lam, and Rando Allikmets, and Edwin M Stone
January 1997, Retina (Philadelphia, Pa.),
Saloni Walia, and Gerald A Fishman, and Samuel G Jacobson, and Tomas S Aleman, and Robert K Koenekoop, and Elias I Traboulsi, and Richard G Weleber, and Mark E Pennesi, and Elise Heon, and Arlene Drack, and Byron L Lam, and Rando Allikmets, and Edwin M Stone
October 1985, Archives of ophthalmology (Chicago, Ill. : 1960),
Saloni Walia, and Gerald A Fishman, and Samuel G Jacobson, and Tomas S Aleman, and Robert K Koenekoop, and Elias I Traboulsi, and Richard G Weleber, and Mark E Pennesi, and Elise Heon, and Arlene Drack, and Byron L Lam, and Rando Allikmets, and Edwin M Stone
January 1991, Archives of ophthalmology (Chicago, Ill. : 1960),
Saloni Walia, and Gerald A Fishman, and Samuel G Jacobson, and Tomas S Aleman, and Robert K Koenekoop, and Elias I Traboulsi, and Richard G Weleber, and Mark E Pennesi, and Elise Heon, and Arlene Drack, and Byron L Lam, and Rando Allikmets, and Edwin M Stone
May 2017, Oncotarget,
Saloni Walia, and Gerald A Fishman, and Samuel G Jacobson, and Tomas S Aleman, and Robert K Koenekoop, and Elias I Traboulsi, and Richard G Weleber, and Mark E Pennesi, and Elise Heon, and Arlene Drack, and Byron L Lam, and Rando Allikmets, and Edwin M Stone
March 2015, Molecular medicine reports,
Saloni Walia, and Gerald A Fishman, and Samuel G Jacobson, and Tomas S Aleman, and Robert K Koenekoop, and Elias I Traboulsi, and Richard G Weleber, and Mark E Pennesi, and Elise Heon, and Arlene Drack, and Byron L Lam, and Rando Allikmets, and Edwin M Stone
January 2002, Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde,
Saloni Walia, and Gerald A Fishman, and Samuel G Jacobson, and Tomas S Aleman, and Robert K Koenekoop, and Elias I Traboulsi, and Richard G Weleber, and Mark E Pennesi, and Elise Heon, and Arlene Drack, and Byron L Lam, and Rando Allikmets, and Edwin M Stone
May 1985, The British journal of ophthalmology,
Saloni Walia, and Gerald A Fishman, and Samuel G Jacobson, and Tomas S Aleman, and Robert K Koenekoop, and Elias I Traboulsi, and Richard G Weleber, and Mark E Pennesi, and Elise Heon, and Arlene Drack, and Byron L Lam, and Rando Allikmets, and Edwin M Stone
January 1991, Bulletin de la Societe belge d'ophtalmologie,
Copied contents to your clipboard!